Corinne Schär
4 Papers
6 Citations
Corinne Schär is an academic researcher. The author has contributed to research in topics: Denosumab & Quality of life. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
R. von Moos,Hanne Hawle,Stefanie Hayoz,Richard Cathomas,A. Müller,Sabine Schmid,O. Pagani,Tobias Wehrhahn,Dieter Rauch,Sandro Anchisi,Thomas Hermanns,Mathias K. Fehr,Susanna Stoll,P Butzberger,Martin Zweifel,Urs Huber,Andrea Fuhrer,Corinne Schär,Silke Gillessen,Arnoud J. Templeton +19 more
4
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
Andreas Müller,Arnoud J. Templeton,Stefanie Hayoz,Hanne Hawle,U Hasler-Strub,Michael Schwitter,B. Pestalozzi,O. Pagani,P Butzberger,Tobias Wehrhahn,Dieter Rauch,R. Inauen,Daniel C. Betticher,Khan Shah Zaman,Alexandre Bodmer,R. A. Popescu,Sacha I. Rothschild,J Schardt,Markus Borner,Andrea Fuhrer,Corinne Schär,Silke Gillessen,R. von Moos +22 more
TL;DR: Up to 20% of all BC patients treated with DN experienced HC in the q4w induction phase despite mandatory supplementation of VitD and Ca, considerably higher than the numbers reported in the registration trials of DN.
3
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Michael Mark,Beat Thürlimann,Karin Ribi,Corinne Schär,Daniel Dietrich,Richard Cathomas,Ursina Zürrer-Härdi,Thomas von Briel,Sandro Anchisi,Pierre Bohanes,Veronika Blum,Philipp von Burg,Meinrad Mannhart,Clemens B. Caspar,Roger von Moos +14 more
TL;DR: Bone pain and SRE incidence were low in patients with solid tumor bone metastases, which may indicate BTA efficacy and judicious BTA prescribing.
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Karin Ribi,Beat Thürlimann,Corinne Schär,Daniel Dietrich,Richard Cathomas,Ursina Zürrer-Härdi,Thomas von Briel,Sandro Anchisi,Pierre Oliver Bohanes,Veronika Blum,Philippe von Burg,Meinrad Mannhart,Clemens B. Caspar,Roger von Moos,Michael Mark +14 more
TL;DR: In this article, the impact of bone-targeted agents (BTAs) on patient-reported pain and bone pain-related quality of life (QoL) was investigated.